Science Explorer Back to mapMap

Most cited papers from Akston Biosciences (United States)

What are the most cited papers from Akston Biosciences (United States)?

The most cited paper from Akston Biosciences (United States) is "FSH blockade improves cognition in mice with Alzheimer’s disease" (Jing Xiong et al., 2022), with 353 citations. Next come "A First Version of the Caenorhabditis elegans Promoterome" (180) and "C. elegans ORFeome Version 3.1: Increasing the Coverage of ORFeome Resources With Improved Gene Predictions" (118).

Showing 16 of 16 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 FSH blockade improves cognition in mice with Alzheimer’s disease Jing Xiong et al. · Nature Open access 2 Mar 2022 353
2 A First Version of the Caenorhabditis elegans Promoterome Denis Dupuy, Qianru Li, Bart Deplancke et al. · Genome Research Open access 15 Oct 2004 180
3 C. elegans ORFeome Version 3.1: Increasing the Coverage of ORFeome Resources With Improved Gene Predictions Philippe Lamesch, Stuart Milstein, Tong Hao et al. · Genome Research Open access 15 Oct 2004 118
4 Generation of the Brucella melitensis ORFeome Version 1.1: Figure 1 Amélie Dricot et al. · Genome Research Open access 15 Oct 2004 76
5 Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452 David G. Alleva et al. · Vaccine Open access Oct 2021 45
6 Shift to high‐intensity, low‐volume perfusion cell culture enabling a continuous, integrated bioprocess Matthew Gagnon, Shashikant Nagre, Wenge Wang et al. · Biotechnology Progress 9 Oct 2018 45
7 Ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in dogs Sean E. Hulsebosch, Jully Pires, Michael J. Bannasch et al. · Journal of Veterinary Internal Medicine Open access 27 May 2022 25
8 Novel, linked bioreactor system for continuous production of biologics Matthew Gagnon, Shashikant Nagre, Wenge Wang et al. · Biotechnology and Bioengineering 6 Apr 2019 22
9 Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452 Yester F. Janssen et al. · Vaccine Open access 31 Jan 2022 17
10 A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452 Eline A. Feitsma et al. · Vaccine Open access 23 Feb 2023 16
11 An antigen-specific immunotherapeutic, AKS-107, deletes insulin-specific B cells and prevents murine autoimmune diabetes David G. Alleva, Andrea R. Delpero, Thillainaygam Sathiyaseelan et al. · Frontiers in Immunology Open access 7 Mar 2024 8
12 An ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in cats Chen Gilor, Sean E. Hulsebosch, Jully Pires et al. · Journal of Veterinary Internal Medicine Open access Jul 2021 7
13 Brain Atlas for Glycoprotein Hormone Receptors at Single-Transcript Level Vitaly Ryu et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access Jun 2022 2
14 Academia-Industry Collaboration: An Integral Element for Building “Omic” Resources DAVID EDWIN HILL, Michael A. Brasch, Anthony A. del Campo et al. · Genome Research Open access 15 Oct 2004 2
15 Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine David G. Alleva et al. · npj Vaccines Open access 21 Feb 2024 1
16 The antigen-specific immunotherapy, AKS-107, selectively depletes anti-insulin B lymphocytes in the pancreas and reduces insulitis in T1D-prone mice 2259549 Tyler Jenkins, Jack McAninch, Dudley McNitt et al. · The Journal of Immunology Open access 28 Jul 2026 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.